SCHEMBL4156358

SCHEMBL4156358

NC(=O)c1ccc(Cc2cccc(Cl)c2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
RAB9A P51151 2/20 0.49
LMNA P02545 1/20 0.48
HTR3E A5X5Y0 2/20 0.47
HTR3B O95264 2/20 0.47
HTR3A P46098 2/20 0.47
HTR3D Q70Z44 2/20 0.47
HTR3C Q8WXA8 2/20 0.47
F2 P00734 1/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
ABL1 P00519 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28147116 0.88 LMNA (0.50) HTTRAB9ALMNAHTR3EHTR3B
SCHEMBL4159536 0.82 MAOB (0.45) HTTRAB9AF2DYRK1AGPR52
SCHEMBL4158801 0.81 ALOX5 (0.51) HTTRAB9ALMNAF2KDM4E
SCHEMBL7826555 0.80 FEN1 (0.52) HTTRAB9ALMNAKDM4EMAPT
SCHEMBL1680462 0.76 PNMT (0.58) LMNAHTR3EHTR3BHTR3AHTR3D
SCHEMBL17398547 0.74 LMNA (0.47) HTTRAB9ALMNAKDM4EMAPT
SCHEMBL1680944 0.74 MAPT (0.44) HTTRAB9ALMNAKDM4EMAPT
SCHEMBL7081256 0.74 LMNA (0.47) HTTRAB9ALMNAKDM4EMAPT
SCHEMBL30579047 0.73 LMNA (0.44) HTTRAB9ALMNAKDM4EMAPT
SCHEMBL1680353 0.73 LMNA (0.44) HTTRAB9ALMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD HTT 3374/4885RAB9A 391/4885LMNA 698/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 HTT 4819/4885RAB9A 1739/4885LMNA 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.